STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
BLCM BELLICUM PHARMACEUTICALS StockScouter® Report
5
StockScouter® Score
BELLICUM PHARMACEUTICALS, a micro cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with higher than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- The enterprise value-to-sales ratio is much lower than the average for comparably-sized companies in the StockScouter universe. Very Positive
- The most recent quarterly earnings report higher than analysts’ consensus forecast. Positive
Concerns
- Earnings growth in the past year has decelerated rapidly compared to earnings growth in the past three years. Negative
- Moving average analysis for BLCM suggests weak price movement over the medium term. Negative
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that micro cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.
Expected Risk/Return
Core Model Grades
D
C
A
C